The role of SGLT2 inhibitors in managing type 2 diabetes

被引：19

作者：

Tat, Velen ^{[1
,2
]}

Forest, Christopher P. ^{[3
,4
]}

机构：

[1] Arrowhead Reg Med Ctr, Colton, CA 92324 USA

[2] Univ Southern Calif, Keck Sch Med, Primary Care PA Program, Alhambra, CA USA

[3] Calif State Univ Monterey Bay, Hlth Sci & Human Serv, Seaside, CA USA

[4] Master Sci PA Program, Seaside, CA USA

来源：

JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS | 2018年 / 31卷 / 06期

关键词：

SGLT2; inhibitor; diabetes; canagliflozin; dapagliflozin; empagliflozin; ertugliflozin; major adverse cardiac event; COTRANSPORTER; 2; INHIBITORS;

D O I：

10.1097/01.JAA.0000533660.86287.04

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The sodium glucose cotransporter 2 (SGLT2) inhibitors canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin represent a novel class of medications to manage type 2 diabetes through urinary excretion of glucose. These drugs block glucose reabsorption by the kidneys to increase glucosuria. These drugs provide hemoglobin A1C reduction, promote weight loss, and remain hypoglycemic-neutral when not used in combination with insulin or secretagogues. Canagliflozin and empagliflozin have shown cardiovascular benefit. The potential to reduce the risk of cardiovascular death in patients with type 2 diabetes, along with the benefit of weight reduction, makes these new agents useful tools for the primary care provider.

引用

页码：35 / 40

页数：6

共 21 条

[11] From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus [J].

DeFronzo, Ralph A. .

DIABETES, 2009, 58 (04) :773-795

[12] Association of Cardiometabolic Multimorbidity With Mortality The Emerging Risk Factors Collaboration [J].

Di Angelantonio, Emanuele ;

Kaptoge, Stephen ;

Wormser, David ;

Willeit, Peter ;

Butterworth, Adam S. ;

Bansal, Narinder ;

O'Keeffe, Linda M. ;

Gao, Pei ;

Wood, Angela M. ;

Burgess, Stephen ;

Freitag, Daniel F. ;

Pennells, Lisa ;

Peters, Sanne A. ;

Hart, Carole L. ;

Haheim, Lise Lund ;

Gillum, Richard F. ;

Nordestgaard, Borge G. ;

Psaty, Bruce M. ;

Yeap, Bu B. ;

Knuiman, Matthew W. ;

Nietert, Paul J. ;

Kauhanen, Jussi ;

Salonen, Jukka T. ;

Kuller, Lewis H. ;

Simons, Leon A. ;

van der Schouw, Yvonne T. ;

Barrett-Connor, Elizabeth ;

Selmer, Randi ;

Crespo, Carlos J. ;

Rodriguez, Beatriz ;

Verschuren, W. M. Monique ;

Salomaa, Veikko ;

Svardsudd, Kurt ;

van der Harst, Pim ;

Bjorkelund, Cecilia ;

Wilhelmsen, Lars ;

Wallace, Robert B. ;

Brenner, Hermann ;

Amouyel, Philippe ;

Barr, Elizabeth L. M. ;

Iso, Hiroyasu ;

Onat, Altan ;

Trevisan, Maurizio ;

D'Agostino, Ralph B., Sr. ;

Cooper, Cyrus ;

Kavousi, Maryam ;

Welin, Lennart ;

Roussel, Ronan ;

Hu, Frank B. ;

Sato, Shinichi .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (01) :52-60

[13] SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System [J].

Fadini, Gian Paolo ;

Bonora, Benedetta Maria ;

Avogaro, Angelo .

DIABETOLOGIA, 2017, 60 (08) :1385-1389

[14] CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2018 EXECUTIVE SUMMARY [J].

Garber, Alan J. ;

Abrahamson, Martin J. ;

Barzilay, Joshua I. ;

Blonde, Lawrence ;

Bloomgarden, Zachary T. ;

Bush, Michael A. ;

Dagogo-Jack, Samuel ;

DeFronzo, Ralph A. ;

Einhorn, Daniel ;

Fonseca, Vivian A. ;

Garber, Jeffrey R. ;

Garvey, W. Timothy ;

Grunberger, George ;

Handelsman, Yehuda ;

Hirsch, Irl B. ;

Jellinger, Paul S. ;

McGill, Janet B. ;

Mechanick, Jeffrey I. ;

Rosenblit, Paul D. ;

Umpierrez, Guillermo E. .

ENDOCRINE PRACTICE, 2018, 24 (01) :91-120

[15] Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology [J].

Kalra, Sanjay .

DIABETES THERAPY, 2014, 5 (02) :355-366

[16]

Kalyani RR, 2018, DIABETES CARE, V41, pS3, DOI [10.2337/dc18-Sppc01, 10.2337/dc18-SPPC01]

[17] Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus [J].

Liakos, Aris ;

Karagiannis, Thomas ;

Bekiari, Eleni ;

Boura, Panagiota ;

Tsapas, Apostolos .

THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2015, 6 (02) :61-67

[18] Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes [J].

Neal, Bruce ;

Perkovic, Vlado ;

Mahaffey, Kenneth W. ;

de Zeeuw, Dick ;

Fulcher, Greg ;

Erondu, Ngozi ;

Shaw, Wayne ;

Law, Gordon ;

Desai, Mehul ;

Matthews, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (07) :644-657

[19]

Sarwar N, 2010, LANCET, V375, P2215, DOI 10.1016/S0140-6736(10)60484-9

[20] The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes [J].

Whalen, Karen ;

Miller, Shannon ;

St Onge, Erin .

CLINICAL THERAPEUTICS, 2015, 37 (06) :1150-1166

← 1 2 3 →